Novartis Bioventures Ltd 3
3 · Galera Therapeutics, Inc. · Filed Nov 6, 2019
Insider Transaction Report
Form 3
Novartis Bioventures Ltd
10% Owner
Holdings
- (indirect: See footnote)
Series A Preferred Stock
→ Common Stock (1,779,864 underlying) - (indirect: See footnote)
Series B Preferred Stock
→ Common Stock (1,423,891 underlying) - (indirect: See footnote)
Series C Preferred Stock
→ Common Stock (89,311 underlying)
Footnotes (2)
- [F1]Novartis Bioventures Ltd. Is the record holder of the securities reported herein. As the indirect parent of Novartis Bioventures Ltd., Novartis AG may be deemed to share beneficial ownership of these securities.
- [F2]Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock on a 0.197763-for-one basis at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering.